Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 19/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL3536603 | 1.00 | HRH3 (0.89) | HRH3 | |
| SCHEMBL1382602 | 0.94 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3532958 | 0.87 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1383657 | 0.85 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1384234 | 0.85 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1384478 | 0.85 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1384369 | 0.83 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3534195 | 0.83 | HRH3 (0.79) | HRH3 | |
| SCHEMBL1385540 | 0.82 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1385615 | 0.81 | HRH3 (1.00) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747203-A4 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | claimed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | claimed |
| EP-1747203-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | claimed |
| WO-2005110998-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | claimed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | claimed |
| US-7807837-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-04 | — | — | US | disclosed |
| EP-1747203-A4 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| EP-1747203-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005110998-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | ABL1, NOS2, FLT3 | HRH3 2308/4885 |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | ABL1, NOS2, FLT3 | HRH3 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.